StockNews.com started coverage on shares of Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) in a report released on Thursday. The brokerage issued a sell rating on the stock.
RETA has been the topic of a number of other research reports. SVB Securities increased their price objective on Reata Pharmaceuticals from $35.00 to $75.00 in a report on Wednesday, March 1st. Citigroup increased their price target on shares of Reata Pharmaceuticals from $53.00 to $120.00 and gave the stock a buy rating in a report on Wednesday, March 1st. The Goldman Sachs Group boosted their price objective on shares of Reata Pharmaceuticals from $115.00 to $117.00 and gave the company a buy rating in a research note on Friday, February 24th. Stifel Nicolaus increased their target price on shares of Reata Pharmaceuticals from $75.00 to $105.00 in a research note on Wednesday, March 1st. Finally, Robert W. Baird boosted their price target on shares of Reata Pharmaceuticals from $40.00 to $85.00 and gave the company a neutral rating in a research report on Wednesday, March 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $95.00.
Reata Pharmaceuticals Price Performance
Shares of RETA stock opened at $85.29 on Thursday. The company’s fifty day simple moving average is $53.94 and its two-hundred day simple moving average is $39.89. Reata Pharmaceuticals has a 1 year low of $18.47 and a 1 year high of $95.00.
Institutional Investors Weigh In On Reata Pharmaceuticals
A number of hedge funds have recently made changes to their positions in RETA. Wellington Management Group LLP grew its holdings in shares of Reata Pharmaceuticals by 3.4% during the 1st quarter. Wellington Management Group LLP now owns 4,396,539 shares of the company’s stock valued at $144,030,000 after purchasing an additional 143,562 shares during the last quarter. Vanguard Group Inc. increased its stake in Reata Pharmaceuticals by 1.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,653,300 shares of the company’s stock worth $66,677,000 after purchasing an additional 33,890 shares during the period. BlackRock Inc. boosted its stake in shares of Reata Pharmaceuticals by 15.5% during the third quarter. BlackRock Inc. now owns 2,495,371 shares of the company’s stock valued at $62,709,000 after purchasing an additional 335,724 shares during the period. First Light Asset Management LLC grew its holdings in shares of Reata Pharmaceuticals by 95.5% in the fourth quarter. First Light Asset Management LLC now owns 2,062,453 shares of the company’s stock worth $78,353,000 after purchasing an additional 1,007,468 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Reata Pharmaceuticals in the third quarter worth $45,502,000. 76.13% of the stock is currently owned by institutional investors.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
- Get a free copy of the StockNews.com research report on Reata Pharmaceuticals (RETA)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.